Patient-reported outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study is tracking how people with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan or other chemotherapy. It aims to understand real-world benefits from the patient's perspective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your breast cancer has spread to other parts of the body (metastatic) and is triple-negative (negative for hormones and HER2).
- You have already had at least one treatment for your metastatic breast cancer.
- You are planning to receive, or have already received, the study drug (sacituzumab govitecan) or another chemotherapy your doctor chooses.
- You are not pregnant or breastfeeding, and your liver function is not severely impaired.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.